Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide as Maintenance

Status Active, not recruiting

Clinical Trial Summary

Tenofovir alafenamide (TAF), active against both HIV and HBV, demonstrates similar antiviral efficacy but improved renal and bone safety compared to tenofovir disoproxil fumarate (TDF) in HIV-1-infected patients. HIV-1-infected patients whose estimated glomerular filtration rate (eGFR) between 30-69 mL/min were shown to have minimal change in eGFR and improved proteinuria, albuminuria, and bone mineral density after switching to a single-tablet regimen containing Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (EVG/cob/FTC/TAF). For treatment of chronic HBV infection, a similar proportion of HBV-monoinfected patients who received TAF and those who received TDF achieved undetectable HBV DNA at 48 weeks of therapy. Although TAF is effective for HIV and HBV suppression, data on efficacy of TAF are limited among patients co-infected with both viruses. Currently, only one open-label, single-arm study had investigated the efﬁcacy and safety of TAF in HIV/HBV-coinfected patients. In this study, 72 HIV/HBV-coinfected patients switching to EVG/cob/FTC/TAF were enrolled, and 91.7% of them maintained or achieved virologic suppression for both HIV and HBV at 48 weeks of therapy. Seroconversion occurred in 2.9% of HBsAg-positive participants and in 3.3% of HBeAg-positive participants. Improvements in eGFR and declines in markers of bone turnover of the participants were observed. The limitations of the above study are the small sample size. Taiwan is a country hyperendemic for HBV infection, with 19.8% of HIV-positive patients who were born before the implementation of nationwide neonatal vaccination in 1986 had concurrent chronic HBV infection. To further the understanding of the difference between TAF- and TDF-containing combination antiretroviral therapy among HIV/HBV-coinfected patients, the investigators plan to conduct an observational study to evaluate the efficacy and safety of EVG/cob/FTC/TAF as maintenance treatment of HIV/HBV-coinfected patients.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03425994
Study type	Observational [Patient Registry]
Source	National Taiwan University Hospital
Contact
Status	Active, not recruiting
Phase
Start date	February 6, 2018
Completion date	October 11, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03550794` - Thiamine as a Renal Protective Agent in Septic Shock	Phase 2
Terminated	`NCT04051957` - Isosorbide Mononitrate For Anti-Vascular Endothelial Growth Factor (VEGF) Induced Kidney Injury	Phase 2
Completed	`NCT04985292` - Does Probiotic Supplementation Prevent Kidney Injury During Strenuous Physical Exercise?	N/A
Completed	`NCT04933604` - LPN in Patients With High-complex Renal Tumors
Recruiting	`NCT05229328` - Study on the Establishment of a System for Early Warning and Prognostic Evaluation of Patients With Sepsis
Completed	`NCT02242006` - Antimicrobial Pharmacokinetics in Critically Ill Adults During Sustained Low Efficiency Dialysis (SLED)
Terminated	`NCT05747053` - Personalization of Immunosuppressive Treatment for Organ Transplant Recipients
Completed	`NCT03407573` - Restrictive vs Liberal Transfusion Strategy on Cardiac Injury in Patients Undergoing Surgery for Fractured Neck Of Femur	N/A
Withdrawn	`NCT00793013` - Airway Pressure Release Ventilation (APRV) Compared to ARDSnet Ventilation	Phase 2
Not yet recruiting	`NCT06108765` - Acute Kidney Injury in Poly Trauma Patients
Recruiting	`NCT05155358` - Study on the Establishment of a System for Early Warning and Prognostic Evaluation of Patients With Heat Stroke
Completed	`NCT06008223` - Clinical Analysis of Vitamin B6 in Sepsis	N/A
Completed	`NCT04869462` - DS Titanium Ligation Clip in Urology (Prostatectomy and Nephrectomy)
Recruiting	`NCT04626323` - Randomized Study Comparing Metabolic Surgery With Intensive Medical Therapy to Treat Diabetic Kidney Disease	Phase 2
Active, not recruiting	`NCT02037321` - Meta-Analyses of the Effect of Vegetable Protein for Animal Protein on Cardiometabolic Risk	N/A
Completed	`NCT00819871` - Nuclear Factor Kappa-B (NFKB1) Polymorphism and Organ Injury After Cardiac Surgery	N/A
Recruiting	`NCT05812755` - SGC Stimulation, Perioperative Vascular Reactivity, and Organ Injury in Cardiac Surgery	Phase 4
Recruiting	`NCT04902846` - Immune Checkpoint Inhibitors Nephrotoxicity
Recruiting	`NCT04752293` - Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE)
Completed	`NCT03139123` - Prevalence of Hypotension Associated With Preload Dependence During Continuous Renal Replacement Therapy

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide as Maintenance Treatment for HIV/HBV-coinfection

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms